FDA-Cleared Blood Test for Alzheimer’s Assessment in Primary Care Now Available Nationwide
The Elecsys pTau-181 test helps primary care clinicians rule out Alzheimer's disease in symptomatic patients aged 55 and older.
Category: Dementias & Alzheimer’s
Dementias & Alzheimer’s
Latest
Dementias & Alzheimer’s
Latest
Digital Cognitive Test Helps Identify Primary Care Patients Who Need Alzheimer’s Blood Biomarker Testing
Researchers say the digital assessment improves early identification of patients likely to benefit from blood biomarker testing for Alzheimer’s disease.
Dementias & Alzheimer’s
Latest
C2N Diagnostics Lowers Age Limit for Alzheimer’s Blood Test to 50
C2N Diagnostics has expanded the intended use of its PrecivityAD2 Alzheimer's disease blood test to include patients 50 years and older, lowering the previous age limit from 60 years.
Roche Shares Alzheimer’s Drug and Diagnostic Advances at AAIC 2025
At the Alzheimer’s Association International Conference, Roche shared new data on its investigational antibody trontinemab and its Elecsys pTau217 blood test.
Read More
Blood-Based Biomarkers Are Advancing Alzheimer’s Testing
Blood-based biomarker tests are revolutionizing Alzheimer’s diagnostic testing and management of Alzheimer’s disease.
Read More
Alzheimer’s Biomarkers Can Be Detected as Early as Middle Age
A Finnish study reveals that Alzheimer’s-related blood biomarkers can be detected in middle age, potentially spotting the disease sooner.
Read More
Are AI-Powered Neurodiagnostic Solutions the New Frontier in Alzheimer’s Prevention?
AI-enhanced EEG technology offers a promising, accessible way to detect early signs of Alzheimer’s disease—years before symptoms appear.
Read More
Quest Diagnostics to Offer Fujirebio Blood Test for Alzheimer’s
Quest Diagnostics will offer a Fujirebio blood test this summer to enhance early detection of Alzheimer’s disease.
Read More
Simoa Technology Platform Expands Into New Market
Quanterix Corporation’s HD-X Simoa Immunoassay Analyzer has received Class 1 Medical Device registration in South Korea.
Read More
Blood Test for Alzheimer’s Cleared by FDA
An FDA-cleared blood test that measures key Alzheimer’s disease biomarkers is a less invasive, more accurate method to diagnose the condition.
Read More
Test Detects P-SYN in Skin Biopsies of Patients with iRBD
Summary: CND Life Sciences has released baseline results from its NIH-funded Syn-Sleep Study,...
Read More
NULISAseq CNS Disease Panel 120 Expanded with Blood-Based Brain-Derived pTau Assays
Alamar Biosciences has expanded its NULISAseq CNS Disease Panel 120 to include highly sensitive, blood-based assays.
Read More
Astrocytes Play Key Role in Alzheimer’s Disease
Researchers have identified the key enzyme causing Alzheimer’s disease by linking it to excessive GABA production in reactive astrocytes.
Read More
Blood Test Provides Accurate Results for Alzheimer’s Detection
A large international study found that a simpler blood test method using plasma P-tau217 can accurately detect Alzheimer’s disease.
Read More
Parkinson’s Disease Needs Improved Diagnostic Processes
A study found that up to 17.7% of initial Parkinson’s disease diagnoses are later revised, highlighting the challenges of its diagnosis.
Read More
Blood-Based Biomarker Test Accelerates Path to Diagnosis of Alzheimer’s Disease
Labcorp has launched a nationwide blood-based biomarker test, the pTau-217/Beta Amyloid 42 Ratio, to aid in diagnosing Alzheimer’s disease.
Read More
pTau217 Antibody Demonstrates High Rate of Reliability and Scalability
ALZpath, Inc. announced that it presented data from evaluations of its proprietary pTau217 antibody for blood-based Alzheimer’s diagnostics.
Read More
Alzheimer’s Disease Diagnosed with Highly Accurate Blood Test
A new blood test for Alzheimer’s disease not only aids in diagnosis but also helps determine the disease’s progression.
Read More